Amneal Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 2, 2020 and accepted by EDGAR at Mar 2, 2020, 16:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $397.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2019-01-01 to 2019-12-31 | $1.63bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2019-01-01 to 2019-12-31 | $1.15bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2019-10-01 to 2019-12-31 | $110.2m | us-gaap:GrossProfit |
| Gross profit | 12 months2019-01-01 to 2019-12-31 | $353.0m | us-gaap:GrossProfit |
| Research and development | 12 months2019-01-01 to 2019-12-31 | $188.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2019-01-01 to 2019-12-31 | $289.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$248.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2019-01-01 to 2019-12-31 | $383.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$64.9m | us-gaap:ProfitLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$361.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$0.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | −$0.23 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | $1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $47.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2019-01-01 to 2019-12-31 | $0 | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2019-12-31 | $151.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $1.21bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $3.67bn | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $550.4m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2019-12-31 | $2.61bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2019-12-31 | $21.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2019-12-31 | $232.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-008179. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.